On Tuesday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was -5.74% drop from the session before ,before settling in for the closing price of $28.75. A 52-week range for FDMT has been $9.44 – $36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 111.29% over the last five years. When this article was written, the company’s average yearly earnings per share was at -13.51%. With a float of $43.59 million, this company’s outstanding shares have now reached $49.78 million.
The firm has a total of 147 workers. Let’s measure their productivity.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 4D Molecular Therapeutics Inc stocks. The insider ownership of 4D Molecular Therapeutics Inc is 12.43%, while institutional ownership is 74.92%. The most recent insider transaction that took place on Apr 01 ’24, was worth 259,102. In this transaction Chief Legal Officer of this company sold 8,153 shares at a rate of $31.78, taking the stock ownership to the 1,737 shares. Before that another transaction happened on Mar 27 ’24, when Company’s Chief Legal Officer sold 5,833 for $35.04, making the entire transaction worth $204,410. This insider now owns 1,737 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted -$0.75 earnings per share (EPS) during the time that was less than consensus figure (set at -$0.74) by -$0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.51% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
You can see what 4D Molecular Therapeutics Inc (FDMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 61.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -3.40 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 0.55 million was lower than the volume posted last year of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 13.71%. Additionally, its Average True Range was 2.01.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 64.41%, which indicates a significant increase from 3.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.57% in the past 14 days, which was lower than the 119.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.30, while its 200-day Moving Average is $18.73. Now, the first resistance to watch is $28.61. This is followed by the second major resistance level at $30.13. The third major resistance level sits at $31.03. If the price goes on to break the first support level at $26.19, it is likely to go to the next support level at $25.29. Now, if the price goes above the second support level, the third support stands at $23.77.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are 49,778K outstanding shares of the company, which has a market capitalization of 1.35 billion. As of now, sales total 20,720 K while income totals -100,840 K. Its latest quarter income was 20,200 K while its last quarter net income were -10,260 K.
